A practical synthesis of multitargeted antifolate LY231514

被引:34
|
作者
Barnett, CJ [1 ]
Wilson, TM [1 ]
Kobierski, ME [1 ]
机构
[1] Lilly Res Labs, Clin Proc Res & Dev Div, Indianapolis, IN 46285 USA
关键词
D O I
10.1021/op9802172
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
A concise and scalable synthesis of LY231514 (1), a new pyrrolo[2,3-d]pyrimidine-based antitumor agent, is presented. Reaction of 2-bromo-4-arylbutanal 9 with 2,4-diamino-6-hydroxypyrimidine (10) regioselectively provided pyrrolo[2,3-d] pyrimidine 11, representing the core structure of the drug, in good yield. Assimilation of the glutamic acid residue by conventional means completed the synthesis. Development of the optimized synthetic route emphasized avoiding isolation of the relatively unstable aldehyde and bromoaldehyde intermediates.
引用
收藏
页码:184 / 188
页数:5
相关论文
共 50 条
  • [21] A phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA, LY231514) with folic acid (FA)
    Hammond, L
    Villalona-Calero, M
    Eckhardt, SG
    Siu, L
    Hidalgo, M
    Thornton, D
    Walling, J
    Baker, S
    Coltman, C
    Von Hoff, D
    Rowinsky, E
    ANNALS OF ONCOLOGY, 1998, 9 : 129 - 129
  • [22] Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer
    Miller, KD
    Picus, J
    Blanke, C
    John, W
    Clark, J
    Shulman, LN
    Thornton, D
    Rowinsky, E
    Loehrer, PJ
    ANNALS OF ONCOLOGY, 2000, 11 (01) : 101 - 103
  • [23] Activity of multitargeted antifolate (Pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma - Results from a phase II study
    John, W
    Picus, J
    Blanke, CD
    Clark, JW
    Schulman, LN
    Rowinsky, EK
    Thornton, DE
    Loehrer, PJ
    CANCER, 2000, 88 (08) : 1807 - 1813
  • [24] In vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines
    Tesei, A
    Ricotti, L
    De Paola, F
    Amadori, D
    Frassineti, GL
    Zoli, W
    CLINICAL CANCER RESEARCH, 2002, 8 (01) : 233 - 239
  • [25] A simple and concise synthesis of LY231514 (MTA)
    Taylor, EC
    Liu, B
    TETRAHEDRON LETTERS, 1999, 40 (21) : 4023 - 4026
  • [26] Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma
    Tonkinson, JL
    Worzalla, JF
    Teng, CH
    Mendelsohn, LG
    CANCER RESEARCH, 1999, 59 (15) : 3671 - 3676
  • [27] Potentiation of the in vitro activity of the multi-targeted antifolate MTA (LY231514) by dipyridamole
    Smith, PG
    Newell, DR
    Barnes, MJ
    Calvert, AH
    Curtin, NJ
    ANNALS OF ONCOLOGY, 1998, 9 : 154 - 154
  • [28] Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
    Rusthoven, JJ
    Eisenhauer, E
    Butts, C
    Gregg, R
    Dancey, J
    Fisher, B
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1194 - 1199
  • [29] A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
    Rinaldi, DA
    Kuhn, JG
    Burris, HA
    Dorr, FA
    Rodriguez, G
    Eckhardt, SG
    Jones, S
    Woodworth, JR
    Baker, S
    Langley, C
    Mascorro, D
    Abrahams, T
    Von Hoff, DD
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (05) : 372 - 380
  • [30] A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
    David A. Rinaldi
    John G. Kuhn
    Howard A. Burris
    F. Andrew Dorr
    Gladys Rodriguez
    S. Gail Eckhardt
    Suzanne Jones
    James R. Woodworth
    Sharyn Baker
    Connie Langley
    David Mascorro
    Trent Abrahams
    Daniel D. Von Hoff
    Cancer Chemotherapy and Pharmacology, 1999, 44 : 372 - 380